Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cd4+ Lymphocyte Deficiency Clear all
Completed Not applicable Interventional

A Study of Two Anti-HIV Drug Combinations

NCT00002203
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Beverly Hills, California • Los Angeles, California • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Not applicable Interventional

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

NCT00000861
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

NCT00000825
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 22, 2026, 9:46 PM EDT
Completed No phase listed Observational

Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients

NCT00001650
View directory record Official record
Conditions
HIV Infection, Acquired Immunodeficiency Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

NCT00001038
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Interleukin-2 Therapy for HIV Infection - Supplemental Procedures

NCT00001354
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
Interleukin-2/Zidovudine (AZT)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:46 PM EDT
Terminated Phase 1 Interventional

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

NCT00757250
View directory record Official record
Conditions
HIV Infections
Interventions
Angiotensin 1-7
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

A Study of CI-1012 in HIV-Infected Patients

NCT00002196
View directory record Official record
Conditions
HIV Infections
Interventions
CI-1012
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Palm Springs, California • San Francisco, California • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066
View directory record Official record
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Not applicable Interventional

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

NCT00002173
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
The Immune Response Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Jul 22, 2026, 9:46 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00002451
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Miami, Florida • Albany, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

NCT00050921
View directory record Official record
Conditions
HIV Infections
Interventions
somatropin, Hepatitis A virus, inactivated, Keyhole-Limpet Hemocyanin
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 9:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

NCT00839436
View directory record Official record
Conditions
Idiopathic CD4+ T-Lymphocytopenia
Interventions
CYT107
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

NCT00002359
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
The Immune Response Corporation
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
54
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:46 PM EDT
Completed No phase listed Observational

Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts

NCT00001319
View directory record Official record
Conditions
CD4 Lymphocytopenia, Idiopathic CD4 Positive T Lymphocytopenia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

NCT00000883
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease

NCT00000729
View directory record Official record
Conditions
HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

NCT00000872
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Days to 2 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Gainesville, Florida • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 9:46 PM EDT
Completed No phase listed Observational

The Effects of Illnesses on HIV Levels in the Body

NCT00000900
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy

NCT00000728
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients

NCT00001357
View directory record Official record
Conditions
HIV Infection
Interventions
Interleukin-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:46 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

NCT00000908
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
53
States / cities
Birmingham, Alabama • Harbor City, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

NCT00001030
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 9:46 PM EDT